Skip to main content

Table 4 Adverse events related to camrelizumab administration in the TACE-Camrelizumab group

From: Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma

Adverse Event

All Events

CTCAE Grade

1

2

 ≥ 3

RCCEP

14 (70.0%)

10 (50.0%)

4 (20.0%)

0 (0%)

Asthenia

4 (20.0%)

4(20.0%)

0 (0%)

0 (0%)

Rash

4 (20.0%)

4 (20.0%)

0(0%)

0 (0%)

Hypothyroidism

2 (10.0%)

2 (10.0%)

0 (0%)

0 (0%)

Pneumonitis

1 (5.0%)

1 (5.0%)

0 (0%)

0 (0%)

  1. CTCAE Common Terminology Criteria for Adverse Events, RCCEP Reactive cutaneous capillary endothelial proliferation